Welcome to our dedicated page for Apollomics news (Ticker: APLM), a resource for investors and traders seeking the latest updates and insights on Apollomics stock.
Apollomics Inc. (Nasdaq: APLM) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative oncology therapies aimed at targeting specific molecular pathways to combat cancer. With a commitment to harnessing the immune system through combination therapies, Apollomics is at the forefront of developing treatments for difficult-to-treat and treatment-resistant cancers.
Originally known as CBT Pharmaceuticals, Apollomics operates with a clear vision of a world without cancer. The company's lead programs include vebreltinib (APL-101), a selective c-Met inhibitor intended for the treatment of non-small cell lung cancer (NSCLC) and other advanced tumors with c-Met alterations, and uproleselan (APL-106), an E-Selectin antagonist designed to be used adjunctively with standard chemotherapy for acute myeloid leukemia (AML).
Apollomics' commitment to rigorous scientific research is evident in their broad pipeline, consisting of nine drug candidates across multiple programs, six of which are currently in clinical stages of development. The company has built strong partnerships and in-licensed assets to advance both preclinical and clinical development programs. These partnerships play a crucial role in enhancing Apollomics' pipeline and expanding the patient populations served.
Recent milestones include:
- Presentation of interim data from the Phase 2 KUNPENG and SPARTA trials, highlighting the efficacy of vebreltinib in NSCLC patients with MetExon14 skipping mutations.
- Completion of patient enrollment in the Phase 3 bridging study of uproleselan in China, targeting relapsed or refractory AML.
- Conditional approval from the National Medical Products Administration (NMPA) of China for vebreltinib, making it the first c-Met inhibitor approved for CNS tumors with c-Met alterations.
As the company continues to advance its clinical trials and expand its therapeutic potential globally, Apollomics remains focused on providing transformative treatments that significantly improve patient outcomes.
Apollomics presented promising data on vebreltinib at the 2024 ASCO Annual Meeting. The Phase 2 and 2/3 trials showed strong efficacy and safety in treating MET-altered tumors, particularly in non-small cell lung cancer (NSCLC) and glioblastoma patients. Key results included a 75% overall response rate (ORR) for NSCLC with MET exon 14-skipping mutations, and a 6.31 months median overall survival (OS) in glioblastoma patients with PTPRZ1-MET Fusion gene. No new safety concerns were identified. Apollomics aims to continue advancing vebreltinib's clinical development.
Apollomics, a clinical-stage biopharmaceutical company focusing on oncology drug candidates, will present at the 2024 BIO International Convention. The event will take place from June 3-6, 2024, in San Diego, California.
Apollomics' presentation, led by President Sanjeev Redkar, PhD, is scheduled for June 4 at 3:15 p.m. in Theater 2, Hall A, at the San Diego Convention Center.
Management will also be available for one-on-one meetings with registered attendees, which can be scheduled through the BIO One-on-One Partnering™ system or by contacting the provided email.
Apollomics Inc. (Nasdaq: APLM) announced a private placement financing of approximately $6 million through subscription agreements for a PIPE financing, with gross proceeds to fund pipeline programs and general corporate purposes. The financing involves the sale of 19,166,666 Class A ordinary shares at $0.30 per share, expected to close on May 8, 2024. Additionally, Dr. Robert Lin, M.D., Ph.D., an experienced physician and researcher, has been appointed to the board of directors, while Jonathan Wang, Ph.D., has resigned. Canaccord Genuity acts as the financial advisor for the financing.
FAQ
What is the current stock price of Apollomics (APLM)?
What is the market cap of Apollomics (APLM)?
What does Apollomics Inc. do?
What are Apollomics' lead programs?
What recent achievements has Apollomics made?
How many drug candidates does Apollomics have in its pipeline?
What is the significance of Apollomics' partnerships?
How does vebreltinib work?
What is uproleselan used for?
What are the key focuses of Apollomics' current research?
What is the significance of Apollomics' recent conditional approval in China?
How does Apollomics plan to continue its growth and advancements in oncology treatments?
